Chihiro Shiraishi

Fukuoka, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 43 publications

Zero Events, Limited Precision, and the Interpretation of Olanzapine Safety in Patients with Diabetes Receiving Cisplatin [Response to Letter].

Zero Events, Limited Precision, and the Interpretation of Olanzapine Safety in Patients with Diabetes Receiving Cisplatin [Response to Letter].

Journal: Drug design, development and therapy

Published: July 30, 2026

Comparative Adverse Event Reporting of Asparaginase-Containing Induction Regimens in Pediatric Acute Lymphoblastic Leukemia Using the United States Food and Drug Administration Adverse Event Reporting System.

Comparative Adverse Event Reporting of Asparaginase-Containing Induction Regimens in Pediatric Acute Lymphoblastic Leukemia Using the United States Food and Drug Administration Adverse Event Reporting System.

Journal: Cureus

Published: May 01, 2026

Hypothesis-Generating Analysis of Four Immunosuppressive Regimens After Simultaneous Pancreas-Kidney Transplantation Using the United States Food and Drug Administration Adverse Event Reporting System.

Hypothesis-Generating Analysis of Four Immunosuppressive Regimens After Simultaneous Pancreas-Kidney Transplantation Using the United States Food and Drug Administration Adverse Event Reporting System.

Journal: Cureus

Published: April 16, 2026

Safety of Short-T erm Low-Dose Olanzapine in Patients with Cancer and Diabetes Receiving Cisplatin-Based Chemotherapy: A Retrospective TriNetX Cohort Study.

Safety of Short-T erm Low-Dose Olanzapine in Patients with Cancer and Diabetes Receiving Cisplatin-Based Chemotherapy: A Retrospective TriNetX Cohort Study.

Journal: Drug design, development and therapy

Published: April 10, 2026

Clinical outcomes of daptomycin in patients with augmented renal clearance: a case series.

Clinical outcomes of daptomycin in patients with augmented renal clearance: a case series.

Journal: Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy

Published: March 13, 2026

Cholecalciferol Supplementation and Transplant Outcomes Across Immunosuppressive Regimens in Renal Transplant Recipients Using the United States Food and Drug Administration Adverse Event Reporting System.

Cholecalciferol Supplementation and Transplant Outcomes Across Immunosuppressive Regimens in Renal Transplant Recipients Using the United States Food and Drug Administration Adverse Event Reporting System.

Journal: Cureus

Published: March 12, 2026

Comparative Safety of Six First-Line Antiepileptic Monotherapies in Pediatric Epilepsy Using the United States FDA Adverse Event Reporting System.

Comparative Safety of Six First-Line Antiepileptic Monotherapies in Pediatric Epilepsy Using the United States FDA Adverse Event Reporting System.

Journal: Cureus

Published: March 11, 2026

Comparison of Adverse Events Associated With Six Common Antibiotics in Lower Respiratory Tract Infections Using the United States Food and Drug Administration Adverse Event Reporting System.

Comparison of Adverse Events Associated With Six Common Antibiotics in Lower Respiratory Tract Infections Using the United States Food and Drug Administration Adverse Event Reporting System.

Journal: Cureus

Published: February 17, 2026

Comparative effectiveness of two first-line, ICI-based regimens for advanced HCC: a target trial emulation using an electronic medical record network.

Comparative effectiveness of two first-line, ICI-based regimens for advanced HCC: a target trial emulation using an electronic medical record network.

Journal: Frontiers in oncology

Published: December 26, 2025

Adverse events associated with single-ingredient folic acid in pregnancy: A descriptive analysis of the United States Food and Drug Administration Adverse Event Reporting System (2004-2025).

Adverse events associated with single-ingredient folic acid in pregnancy: A descriptive analysis of the United States Food and Drug Administration Adverse Event Reporting System (2004-2025).

Journal: Nutrition and health

Published: November 20, 2025

Multiple-day dexamethasone for controlling delayed chemotherapy-induced nausea and vomiting with low-emetic-risk chemotherapy.

Multiple-day dexamethasone for controlling delayed chemotherapy-induced nausea and vomiting with low-emetic-risk chemotherapy.

Journal: BMC cancer

Published: October 17, 2025

Reporting patterns of renal failure associated with immunosuppressant combinations following liver transplantation: a retrospective analysis.

Reporting patterns of renal failure associated with immunosuppressant combinations following liver transplantation: a retrospective analysis.

Journal: Clinical transplantation and research

Published: August 11, 2025

Showing 1-12 of 43

Last Updated: 09/26/2026